WCCT Global Completes Multiple Ethnobridging Studies At Phase I CPUs

COSTA MESA, Calif., Jul. 7, 2015 /PRNewswire-iReach/ -- Contract research organization WCCT Global announced today successful recruitment for and completion of numerous Ethnobridging studies of drugs for diverse therapeutic conditions. Ethnic bridging/Asian bridging studies involve the demonstration of similar safety and pharmacokinetics between peoples from various regions of the world. The results of these ethnic bridging/Asian bridging studies are used to support enrollment of multiple ethnic groups in global clinical trials which ultimately enables acceleration of drug approval for marketing, world-wide. WCCT Global was able to successfully recruit over 200 volunteers, mostly from Chinese and Japanese families, to participate in the research studies. WCCT Global conducted these studies at their two large Phase I CPUs located in Orange County, both at the center of multiple large, metropolitan, ethnically-diverse areas in Southern California.

Photo - http://photos.prnewswire.com/prnh/20150702/227938LOGO

The Ethnobridging programs conducted by WCCT involved assessing the safety of numerous potentially novel therapies for conditions such as osteoarthritis, rheumatoid arthritis, and hepatitis C. Over 200 healthy volunteers were recruited for these programs, the majority of which were of first generation Chinese or Japanese descent in under six weeks. WCCT Global was well equipped to both conduct and recruit for the studies, at their two early phase research facilities with a combined 180 bed capacity, designed for programs requiring large numbers of volunteers. In order to recruit for the study, the CRO turned to its patient recruitment division, IN-SITE, which makes use of advanced technologies that are able to streamline enrollment timelines while providing metrics to measure recruitment campaign success. In addition to the IN-SITE patient recruitment division, WCCT was able to easily recruit for the ethnic bridging programs because of their favorable location at the center of the Orange County and LA areas, which are both home to ethnically-diverse populations, including Asian, Hispanic, and African-Americans.

WCCT Global's Vice President of Early Clinical Development, Ed Kim, had this to say about the contract research organization's ability to successfully recruit and conduct ethnobridging programs: "Over the years, WCCT Global has become well-known for its expertise in conducting ethnobridging and ethnic-sensitivity clinical research. Our facilities are designed specifically to host large, early phase research trials, and our multi-lingual staff is well-trained and prepared for the conduct of these clinical trials. Our years of experience, as well as our unique location within Southern California have encouraged us to adapt as a CRO/CPU and become global authority in managing programs such as these." As a company, WCCT Global firmly believes in the power of conducting ethnobridging research programs and the benefits they offer to the pharmaceutical industry and the potential to get new and important therapies to patients, worldwide.

Media Contact:Matt Miller, WCCT Global, 714.668.1500 ext.2029, Matt.Miller@wcct.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE WCCT Global